When will Intellia Therapeutics submit a BLA for Lonvo-z?

Outcome	Probability	Yes Bid	Yes Ask	24h Change	Volume
before September	0%	0¢	0¢	—	$0	Trade →
before October	0%	0¢	0¢	—	$0	Trade →
before November	0%	0¢	0¢	—	$0	Trade →
before December	0%	0¢	0¢	—	$0	Trade →
before 2027	0%	0¢	0¢	—	$0	Trade →
before April 2027	0%	0¢	0¢	—	$0	Trade →

About This Market

This market asks when Intellia Therapeutics will submit a Biologics License Application (BLA) for Lonvo-z, a development-stage therapeutic, and why that regulatory milestone matters for commercialization and investor expectations.

Intellia is a biotechnology company focused on developing genome-editing and gene-based therapies; a BLA is the formal application to a regulator (most commonly the U.S. FDA) to request approval to market a biologic. Timing of a BLA submission depends on completion and analysis of pivotal studies, readiness of manufacturing and CMC documentation, and prior regulatory interactions.

Market prices reflect traders' aggregated views about the likely timing of a BLA submission given available public and private signals, not a guarantee of outcome. Use the market as a real-time indicator of expectations while monitoring official company and regulator announcements for confirmation.

Key Factors

Pivotal clinical trial status: enrollment completion, primary endpoint achievement, safety profile, and speed of data lock and analysis.
Chemistry, Manufacturing, and Controls (CMC): scale‑up, process validation, stability data, and supply chain readiness required for BLA modules.
Regulatory interactions: pre‑BLA meetings, feedback from the FDA or other regulators on required datasets, and any requests for additional studies.
Corporate decisions and resources: program prioritization within Intellia, partner contributions or licensing agreements, and available funding to support submission activities.
External events and competitors: competing therapies, new safety signals in the field, and changing regulatory guidance for gene‑editing or biologic products.

Frequently Asked Questions

Does this event refer specifically to a BLA submitted to the U.S. Food and Drug Administration (FDA)?

Most markets use 'BLA' to mean a submission to the U.S. FDA; check the market's official rules or description to confirm whether the market uses FDA filing or includes other regulatory jurisdictions.

What counts as a 'BLA submission' for this market—an initial original submission, an amendment, or a resubmission after a Complete Response Letter (CRL)?

Typically the market will count the initial original BLA submission as the milestone; amendments, supplements, or resubmissions after a CRL are usually distinct events, so verify the market wording or rules if unclear.

Which public signals should I watch to update my view on when Intellia might submit a BLA for Lonvo-z?

Watch company press releases and SEC filings for trial completion and data-readout announcements, conference presentations, regulatory meeting summaries, CMC updates, and formal communications with regulators.

How could a surprise safety signal or additional regulatory request affect the expected submission timing for Lonvo-z?

A new safety concern or a regulator request for extra analyses or studies can delay a planned submission by requiring more data collection, protocol amendments, or additional manufacturing validation before a BLA can be filed.

If Intellia announces a partnership or out‑licenses Lonvo-z, how might that change the timing of a BLA submission in this market?

A partnership can accelerate or delay submission depending on resource allocation, access to manufacturing capacity, or strategic reprioritization; any formal deal terms and subsequent joint statements will be important signals to reassess timing.

Trade This Market

About This Market

Key Factors

Frequently Asked Questions